Status:
ACTIVE_NOT_RECRUITING
Stereotactic MRI-guided Radiation Therapy for Localized prostatE Cancer
Lead Sponsor:
University Hospital Heidelberg
Collaborating Sponsors:
Ludwig-Maximilians - University of Munich
University Hospital, Zürich
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
As the most common carcinoma in men, prostate cancer is a significant tumor entity in oncology. In addition to the surgical approach, definitive radiotherapy is an equivalent therapy alternative in th...
Eligibility Criteria
Inclusion
- Histologically confirmed prostate carcinoma with tissue classification according to Gleason score and PSA
- low- or intermediate-risk carcinoma according to d'Amico criteria or early high-risk Carcinoma (cT3a and / or GS ≤ 8 and / or PSA ≤ 20ng / ml)
- IPSS (International Prostate Symptom Score) max. 12
- Prostate volume \<80cm³
- Karnofsky index ≥ 70%
- Age ≥ 18 years
- Patient information provided and written consent
- Ability of the patient to give consent
Exclusion
- Previous radiotherapy in the pelvis
- Previous local therapy of the prostate
- lymphogenic metastasis
- Stage IV (distant metastases)
- Contraindication to MRI
- Simultaneous participation in another clinical study which could influence results of either of the respective study
Key Trial Info
Start Date :
March 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 25 2028
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04845503
Start Date
March 25 2021
End Date
March 25 2028
Last Update
February 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Heidelberg, Radiation Oncology
Heidelberg, Germany, 69120